OnCo
peoplePerson

Yuichiro Ohe

Thoracic oncologist who leads NCC Hospital in Tokyo and has been a Japanese principal investigator on a generation of lung cancer trials.

Yuichiro Ohe has led Japanese participation in EGFR, ALK, and immunotherapy trials in NSCLC and small-cell lung cancer, and directs the National Cancer Center Hospital.

Role
Director, National Cancer Center Hospital; thoracic oncology
Specialisms
Lung cancerChemotherapyTargeted therapyClinical trials

Papers

1top
TitleJournalYear
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)NEJM2018

Key papers

1top
rctNew England Journal of Medicine 2018changed practice
FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer

Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.

Connected

6top

cancers

2
Non-small-cell lung cancerSmall-cell lung cancer

drugs

1
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso

institutions

2
Japanese Society of Medical OncologyNational Cancer Center Hospital

key papers

1
FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer